Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Jul;101(Suppl 1):29–34. doi: 10.1111/j.1365-2249.1995.tb06161.x

European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL.

PMCID: PMC1553550  PMID: 7606858

Full text

PDF
34

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolton W. K., Sturgill B. C. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol. 1989;9(5):368–375. doi: 10.1159/000167998. [DOI] [PubMed] [Google Scholar]
  2. DeRemee R. A. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? Arthritis Rheum. 1988 Aug;31(8):1068–1074. doi: 10.1002/art.1780310821. [DOI] [PubMed] [Google Scholar]
  3. Falk R. J., Hogan S., Carey T. S., Jennette J. C. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med. 1990 Nov 1;113(9):656–663. doi: 10.7326/0003-4819-113-9-656. [DOI] [PubMed] [Google Scholar]
  4. Guillevin L., Lhote F., Jarrousse B., Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) 1992;143(6):405–416. [PubMed] [Google Scholar]
  5. Hagen E. C., Andrassy K., Chernok E., Daha M. R., Gaskin G., Gross W., Lesavre P., Lüdemann J., Pusey C. D., Rasmussen N. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods. 1993 Feb 26;159(1-2):1–16. doi: 10.1016/0022-1759(93)90136-u. [DOI] [PubMed] [Google Scholar]
  6. Hoffman G. S., Leavitt R. Y., Fleisher T. A., Minor J. R., Fauci A. S. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med. 1990 Oct;89(4):403–410. doi: 10.1016/0002-9343(90)90367-m. [DOI] [PubMed] [Google Scholar]
  7. Hoffman G. S., Leavitt R. Y., Kerr G. S., Fauci A. S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992 Nov;35(11):1322–1329. doi: 10.1002/art.1780351113. [DOI] [PubMed] [Google Scholar]
  8. Jayne D. R., Lockwood C. M. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol. 1993;336:469–472. doi: 10.1007/978-1-4757-9182-2_84. [DOI] [PubMed] [Google Scholar]
  9. Jennette J. C., Falk R. J., Andrassy K., Bacon P. A., Churg J., Gross W. L., Hagen E. C., Hoffman G. S., Hunder G. G., Kallenberg C. G. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187–192. doi: 10.1002/art.1780370206. [DOI] [PubMed] [Google Scholar]
  10. Lockwood C. M., Thiru S., Isaacs J. D., Hale G., Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993 Jun 26;341(8861):1620–1622. doi: 10.1016/0140-6736(93)90759-a. [DOI] [PubMed] [Google Scholar]
  11. Luqmani R. A., Bacon P. A., Moots R. J., Janssen B. A., Pall A., Emery P., Savage C., Adu D. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994 Nov;87(11):671–678. [PubMed] [Google Scholar]
  12. Pusey C. D., Rees A. J., Evans D. J., Peters D. K., Lockwood C. M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991 Oct;40(4):757–763. doi: 10.1038/ki.1991.272. [DOI] [PubMed] [Google Scholar]
  13. Rasmussen N., Petersen J. Cellular immune responses and pathogenesis in c-ANCA positive vasculitides. J Autoimmun. 1993 Apr;6(2):227–236. doi: 10.1006/jaut.1993.1020. [DOI] [PubMed] [Google Scholar]
  14. Reinhold-Keller E., Kekow J., Schnabel A., Schmitt W. H., Heller M., Beigel A., Duncker G., Gross W. L. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 1994 Jun;37(6):919–924. doi: 10.1002/art.1780370622. [DOI] [PubMed] [Google Scholar]
  15. Reinhold-Keller E., Kekow J., Schnabel A., Schwarz-Eywill M., Schmitt W. H., Gross W. L. Effectiveness of cyclophosphamide pulse treatment in Wegener's granulomatosis. Adv Exp Med Biol. 1993;336:483–486. doi: 10.1007/978-1-4757-9182-2_87. [DOI] [PubMed] [Google Scholar]
  16. Scott D. G., Watts R. A. Classification and epidemiology of systemic vasculitis. Br J Rheumatol. 1994 Oct;33(10):897–899. doi: 10.1093/rheumatology/33.10.897. [DOI] [PubMed] [Google Scholar]
  17. Stegeman C. A., Tervaert J. W., Sluiter W. J., Manson W. L., de Jong P. E., Kallenberg C. G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994 Jan 1;120(1):12–17. doi: 10.7326/0003-4819-120-1-199401010-00003. [DOI] [PubMed] [Google Scholar]
  18. Tervaert J. W., Huitema M. G., Hené R. J., Sluiter W. J., The T. H., van der Hem G. K., Kallenberg C. G. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 1990 Sep 22;336(8717):709–711. doi: 10.1016/0140-6736(90)92205-v. [DOI] [PubMed] [Google Scholar]
  19. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES